Lung cancer: a cost and outcome study based on physician practice patterns

Disease Management : DM
J Russell Hoverman, S Marciann Robertson

Abstract

Chemotherapy is now an acceptable treatment for selected patients with non-small-cell lung cancer. With the wide assortment of cytotoxic and supportive-care drugs, there are opportunities for assessing the value of various treatment approaches. This study was undertaken to assess variations in treatment patterns in a large oncology group with emphasis on costs incurred and survival. A total of 1215 patients seen in 1996 by Medical Oncologists (a community-based private practice) were identified as new lung cancer patients by review of billing data. Of these, 858 received chemotherapy and were evaluated for charges. Three hundred were evaluated for charges, hospice care, and survival. Differences in practice patterns for physicians and the causes of those differences were assessed. Differences in survival, charges, and hospice care for those patients who were seen by high-charge and low-charge physicians were measured. Clear differences emerged in practice patterns for these Medical Oncologists. Higher charges were associated with higher average number of chemotherapy cycles given, greater use of second- and third-line chemotherapy and greater use of support drugs, particularly G-CSF and erythropoietin. For stage IV non-small-ce...Continue Reading

References

Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J KlasterskyT Michiels
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R GandaraS M Grunberg
Mar 1, 1996·Current Opinion in Oncology·C E DeschT J Smith
Mar 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M BeithJ A Levi
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GlaspyS Vadhan-Raj
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B E HillnerS M Retchin
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Aug 6, 1998·Health Affairs·D M Eddy
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C ChouaidB Housset
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J von PawelR Gralla
Oct 8, 1999·Journal of the National Cancer Institute·J E Groopman, L M Itri
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V LorussoM De Lena
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V A MillerM G Kris
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jul 21, 2000·CA: a Cancer Journal for Clinicians·A K StewartH J Eyre
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MasudaM Fukuoka
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C HuismanP E Postmus
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R YancikB Conley
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I E SmithS Ashley
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LittlewoodUNKNOWN Epoetin Alfa Study Group
Feb 21, 2002·Journal of the National Cancer Institute·Scott D RamseyDavid R Gandara
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A SocinskiMerrill S Kies
Jun 18, 2002·The Oncologist·Scott D Ramsey, Larry G Kessler
May 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiro FukuokaJosé Baselga
Nov 1, 1956·The Journal of Clinical Investigation·R B CHODOSJ F ROSS

❮ Previous
Next ❯

Citations

Mar 5, 2005·Surgery·James W JonesBruce W Richman
May 20, 2014·Journal of Vascular Surgery·James W Jones, Laurence B McCullough
Sep 11, 2007·Journal of Vascular Surgery·James W Jones, Laurence B McCullough
Nov 2, 2006·American Journal of Medical Quality : the Official Journal of the American College of Medical Quality·Chun-Ru Chien, Mei-Shu Lai
Jun 3, 2018·Journal of Medical Economics·Shweta ShahReuben Howden
Oct 30, 2007·Nature Clinical Practice. Oncology·K Robin YabroffMartin L Brown
May 31, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Eugene D Kreys, Jim M Koeller
Oct 4, 2005·Psycho-oncology·Sally E ThorneUNKNOWN SCRN Communication Team
May 6, 2005·Journal of Vascular Surgery·James W JonesBruce W Richman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.